ClinicalTrials.gg
CompletedNCT04968912Updated Nov 5, 2026Results posted

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

A Phase 2 interventional study of Placebo and Nipocalimab in Sjogren's Syndrome, sponsored by Janssen Research & Development, LLC. Completed at 69 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Other

Updated Nov 5, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
23rd of 76
163 · median 57
Started
2021
with 9 others
Phase 2
30 of 111
3 open now
Registered
81st of 111
by date

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 23rd largest by enrollment of the 76 interventional ones that give a count, is one of 10 that started in 2021, is one of 30 in phase 2, and was the 81st registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.

03

Conditions studied

  • Sjogren's Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening (results either obtained during screening or documented in the participant's medical history are acceptable to fulfill these criteria for Schirmer's test, unstimulated salivary flow test, ocular staining score, or labial salivary gland ), and was diagnosed with pSS no less than 26 weeks prior to screening
  • At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's syndrome-related antigen A [SSA])
  • Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (>=) 6
  • At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains
  • It is recommended to be up to date on all age-appropriate vaccinations prior to screening per routine local medical guidelines. It is strongly recommended that participants will have completed a locally-approved (or emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccination regimen at least 2 weeks prior to study related visits or procedures. Study participants should, follow applicable local vaccine labelling, guidelines, and standards-of-care for participants receiving immune-targeted therapy will be followed when determining an appropriate interval between vaccination and study enrollment

Exclusion criteria

Exclusion Criteria:

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her pSS or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Comorbidities (for example, asthma, ) which have required 3 or more courses of systemic within the previous 12 months
  • Has any unstable or progressive manifestation of pSS that is likely to warrant escalation in therapy beyond permitted background medications and/or has severely active pSS
  • Has received oral cyclophosphamide within 3 months or intravenous (IV) cyclophosphamide within 6 months prior to first administration of study intervention
  • Has Sjogren's syndrome overlap syndromes where another confirmed rheumatic or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the primary diagnosis or has clinical manifestations that, in the opinion of the investigator, or the sponsor or sponsor's representative, are likely to interfere with the investigator's ability to assess pSS manifestations
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
163 participants (actual)

Study arms

  • Placebo comparator
    Group 1: Placebo

    Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).

    Other: Placebo · Drug: Standard of Care Treatment

  • Experimental
    Group 2: Nipocalimab Dose 1

    Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).

    Drug: Nipocalimab · Drug: Standard of Care Treatment

  • Experimental
    Group 3: Nipocalimab Dose 2

    Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).

    Drug: Nipocalimab · Drug: Standard of Care Treatment

Interventions

  • OtherPlacebo

    Placebo infusion will be administered intravenously.

  • Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

    Also known as: JNJ-80202135, M281

  • DrugStandard of Care Treatment

    Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24

    In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.

    Time frame: Baseline (Week 0), Week 24

Secondary outcomes

  1. Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24

    Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

    Time frame: Baseline (Week 0), Week 24

  2. Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24

    ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.

    Time frame: Baseline (Week 0), Week 24

  3. Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24

    In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.

    Time frame: Baseline (Week 0), Week 24

  4. Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24

    Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of \>= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

    Time frame: Baseline (Week 0), Week 24

  5. Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24

    Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of \>=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of \>=3 in clinESSDAI score (3), (ii) decrease of \>=1 point or \>=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of \>=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of \>=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of \>=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of \>=25% in rheumatoid factor/decrease of \>=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).

    Time frame: At Week 24

  6. Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24

    DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score \* domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of \>= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).

    Time frame: At Week 24

  7. Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24

    Percentage of participants with improvement from baseline in \>= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in \>= 3 of the following 5 categories: (i) clinESSDAI score less than (\<) 5 (low disease activity), (ii) decrease of \>= 1 point or \>= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (\<= 5 mm) and an increase of \>= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of \>= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of \>= 25% in rheumatoid factor or decrease of \>= 10% in IgG.

    Time frame: At Week 24

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.

    Time frame: Post first administration of study intervention (Week 0) up to Week 30

  9. Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit

    Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin \< 20 grams per liter (g/L) (\< 2.0 grams per deciliter \[g/dL\]); applicable to participants who had albumin greater than (\>) 20 g/L at previous assessments. Those who entered with \< 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin \> 20 g/L or those who entered with albumin \< 20g/L and then had an increase in albumin \> 20 g/L which subsequently decreased to \< 20 g/L were reported as an AESI.

    Time frame: Post first administration of study intervention (Week 0) up to Week 30

  10. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit

    A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.

    Time frame: Post first administration of study intervention (Week 0) up to Week 30

  11. Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit

    Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

    Time frame: Post first administration of study intervention (Week 0) up to Week 30

  12. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (\< 36 degree Celsius and \> 38 degree Celsius), pulse rate (\<= 50 beats per minute \[bpm\] and with \>= 15 bpm decrease from baseline and \>= 120 bpm and with \>= 15 bpm increase from baseline), and blood pressure (systolic blood pressure \[SBP\]: \<= 90 millimeters of mercury \[mmHg\] and with \>= 20 mmHg decrease from baseline and \>= 160 mmHg and with \>= 20 mmHg increase from baseline; diastolic blood pressure \[DBP\]: \<= 50 mmHg and with \>= 15 mmHg decrease from baseline and \>= 100 mmHg and with \>= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.

    Time frame: Post first administration of study intervention (Week 0) up to Week 30

  13. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Laboratory parameters included hematology (platelet count \[platelets: decrease \> 20% and value \< 100)\], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential \[lymphocytes: decrease \> 20% and value \< 0.08\], \[leukocytes: decrease \> 10% and value \< 2.5\], \[neutrophils: increase \> 30% and value \> 0.90\], \[eosinophils: increase \> 20% and value \> 0.10\]), serum chemistry (phosphate \[decrease \> 10% and value \< 0.6), lipid panel (high-density lipoprotein \[HDL\] and low-density lipoprotein \[LDL\], creatine kinase: increase \> 20% and value \> 960, cholesterol: value \>= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, and 30

  14. Serum Nipocalimab Concentration Over Time

    Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.

    Time frame: Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30

  15. Change From Baseline in C-reactive Protein (CRP)

    Change from baseline in CRP were reported.

    Time frame: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30

  16. Change From Baseline in Erythrocyte Sedimentation Rate (ESR)

    Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.

    Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

  17. Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4

    Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.

    Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

  18. Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21

    Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.

    Time frame: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30

  19. Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)

    Change from baseline in autoantibodies included RF were reported.

    Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

  20. Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab

    Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.

    Time frame: Baseline (Week 0) up to Week 30

  21. Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab

    Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.

    Time frame: Baseline (Week 0) up to Week 30

07

Results

Posted Nov 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Started565354
Completed464644
Not completed10710
Withdrew: Lack of efficacy110
Withdrew: Lost to follow-up211
Withdrew: Withdrawal by subject747
Withdrew: Other012

Outcome measures

PrimaryChange From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24

In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.

Time frame:
Baseline (Week 0), Week 24
Reported as:
Mean · Score on a scale
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24
Score on a scaleGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24-3.3 ± 4.72-3.8 ± 3.22-6.7 ± 4.50
Statistical analysis
  • Group 1: Placebo IV q2w vs Group 2: Nipocalimab 5 mg/kg IV q2w · Mixed Models Analysis · p = =0.681 · Mean difference (final values): -0.34 · 90% CI -1.71 to 1.03
  • Group 1: Placebo IV q2w vs Group 3: Nipocalimab 15 mg/kg IV q2w · Mixed Models Analysis · p = =0.002 · Mean difference (final values): -2.65 · 90% CI -4.03 to -1.28
SecondaryChange From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24

Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Time frame:
Baseline (Week 0), Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24
Scores on a scaleGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24-1.8 ± 2.01-1.2 ± 1.90-2.3 ± 1.74
SecondaryPercentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24

ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.

Time frame:
Baseline (Week 0), Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Percentage of participantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 2428.634.046.3
Statistical analysis
  • Group 1: Placebo IV q2w vs Group 2: Nipocalimab 5 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.648 · Difference in proportion: 5.4 · 90% CI -9.2 to 20.0
  • Group 1: Placebo IV q2w vs Group 3: Nipocalimab 15 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.138 · Difference in proportion: 17.7 · 90% CI 2.8 to 32.7
SecondaryPercentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24

In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.

Time frame:
Baseline (Week 0), Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24
Percentage of participantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 2433.937.751.9
Statistical analysis
  • Group 1: Placebo IV q2w vs Group 2: Nipocalimab 5 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.766 · Difference in proportion: 3.8 · 90% CI -11.3 to 18.9
  • Group 1: Placebo IV q2w vs Group 3: Nipocalimab 15 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.138 · Difference in proportion: 17.9 · 90% CI 2.6 to 33.2
SecondaryPercentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24

Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of \>= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Time frame:
Baseline (Week 0), Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24
Percentage of participantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 2450.039.655.6
Statistical analysis
  • Group 1: Placebo IV q2w vs Group 2: Nipocalimab 5 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.280 · Difference in proportion: -10.4 · 90% CI -26.0 to 5.2
  • Group 1: Placebo IV q2w vs Group 3: Nipocalimab 15 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.788 · Difference in proportion: 5.6 · 90% CI -10.1 to 21.2
SecondaryPercentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24

Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of \>=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of \>=3 in clinESSDAI score (3), (ii) decrease of \>=1 point or \>=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of \>=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of \>=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of \>=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of \>=25% in rheumatoid factor/decrease of \>=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24
Percentage of participantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 2439.350.963.0
Statistical analysis
  • Group 1: Placebo IV q2w vs Group 2: Nipocalimab 5 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.218 · Difference in proportion: 11.7 · 90% CI -3.9 to 27.2
  • Group 1: Placebo IV q2w vs Group 3: Nipocalimab 15 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.017 · Difference in proportion: 23.7 · 90% CI 8.4 to 38.9
SecondaryPercentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24

DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score \* domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of \>= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24
Percentage of participantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 2433.952.853.7
Statistical analysis
  • Group 1: Placebo IV q2w vs Group 2: Nipocalimab 5 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.047 · Difference in proportion: 18.9 · 90% CI 3.6 to 34.2
  • Group 1: Placebo IV q2w vs Group 3: Nipocalimab 15 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.046 · Difference in proportion: 19.8 · 90% CI 4.5 to 35.0
SecondaryPercentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24

Percentage of participants with improvement from baseline in \>= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in \>= 3 of the following 5 categories: (i) clinESSDAI score less than (\<) 5 (low disease activity), (ii) decrease of \>= 1 point or \>= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (\<= 5 mm) and an increase of \>= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of \>= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of \>= 25% in rheumatoid factor or decrease of \>= 10% in IgG.

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24
Percentage of participantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 2417.943.448.1
Statistical analysis
  • Group 1: Placebo IV q2w vs Group 2: Nipocalimab 5 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.006 · Difference in proportion: 25.5 · 90% CI 11.5 to 39.5
  • Group 1: Placebo IV q2w vs Group 3: Nipocalimab 15 mg/kg IV q2w · Cochran-Mantel-Haenszel · p = =0.001 · Difference in proportion: 30.3 · 90% CI 16.3 to 44.3
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.

Time frame:
Post first administration of study intervention (Week 0) up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit
ParticipantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit354243
SecondaryNumber of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit

Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin \< 20 grams per liter (g/L) (\< 2.0 grams per deciliter \[g/dL\]); applicable to participants who had albumin greater than (\>) 20 g/L at previous assessments. Those who entered with \< 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin \> 20 g/L or those who entered with albumin \< 20g/L and then had an increase in albumin \> 20 g/L which subsequently decreased to \< 20 g/L were reported as an AESI.

Time frame:
Post first administration of study intervention (Week 0) up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit
ParticipantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit121
SecondaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit

A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.

Time frame:
Post first administration of study intervention (Week 0) up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit
ParticipantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit344
SecondaryNumber of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit

Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Time frame:
Post first administration of study intervention (Week 0) up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit
ParticipantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit233
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (\< 36 degree Celsius and \> 38 degree Celsius), pulse rate (\<= 50 beats per minute \[bpm\] and with \>= 15 bpm decrease from baseline and \>= 120 bpm and with \>= 15 bpm increase from baseline), and blood pressure (systolic blood pressure \[SBP\]: \<= 90 millimeters of mercury \[mmHg\] and with \>= 20 mmHg decrease from baseline and \>= 160 mmHg and with \>= 20 mmHg increase from baseline; diastolic blood pressure \[DBP\]: \<= 50 mmHg and with \>= 15 mmHg decrease from baseline and \>= 100 mmHg and with \>= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.

Time frame:
Post first administration of study intervention (Week 0) up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Pulse: =< 50 bpm and with => 15 bpm010
Pulse:>= 120 bpm and with >= 15 bpm000
SBP: <= 90 mmHg and with >= 20 mmHg311
SBP: >= 160 mmHg and with >= 20 mmHg002
DBP: <= 50 mmHg and with >= 15 mmHg110
DBP: >= 100 mmHg and with >= 15 mmHg001
Temperature: < 36 degree Celsius546
Temperature: > 38 degree Celsius010
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Laboratory parameters included hematology (platelet count \[platelets: decrease \> 20% and value \< 100)\], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential \[lymphocytes: decrease \> 20% and value \< 0.08\], \[leukocytes: decrease \> 10% and value \< 2.5\], \[neutrophils: increase \> 30% and value \> 0.90\], \[eosinophils: increase \> 20% and value \> 0.10\]), serum chemistry (phosphate \[decrease \> 10% and value \< 0.6), lipid panel (high-density lipoprotein \[HDL\] and low-density lipoprotein \[LDL\], creatine kinase: increase \> 20% and value \> 960, cholesterol: value \>= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Week 2: Lymphocytes100
Week 2: Platelets100
Week 4: Phosphate001
Week 4: Cholesterol: Value >= 6.2211
Week 4: HDL Cholesterol: Value >= 2.1137
Week 4: LDL Cholesterol: Value >= 4.1001
Week 4: Leukocytes100
Week 8: Cholesterol: Value >= 6.2121
Week 8: HDL Cholesterol: Value >= 2.1247
Week 8: LDL Cholesterol: Value >= 4.1021
Week 8: Neutrophils010
Week 8: Lymphocytes020
Week 12: HDL Cholesterol: Value >= 2.1136
Week 12: HDL Cholesterol: Value < 1.0010
Week 12: Neutrophils001
Week 12: Lymphocytes011
Week 16: Leukocytes201
Week 24: HDL Cholesterol: Value >= 2.1246
Week 24: LDL Cholesterol: Value >= 4.1020
Week 24: Eosinophils100
Week 24: Creatine Kinase010
Week 24: Cholesterol010
Week 30: Leukocytes010
Week 30: Eosinophils100
SecondarySerum Nipocalimab Concentration Over Time

Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.

Time frame:
Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
Reported as:
Mean · micrograms per milliliter
Serum Nipocalimab Concentration Over Time
micrograms per milliliterGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Week 0, predose0.000 ± 0.00360.001 ± 0.0079
Week 0, postdose108.132 ± 41.1048354.926 ± 129.2114
Week 2, predose0.001 ± 0.00660.004 ± 0.0145
Week 2, postdose98.569 ± 48.0806340.360 ± 130.4009
Week 4, predose0.001 ± 0.00460.001 ± 0.0067
Week 8, predose0.002 ± 0.00820.001 ± 0.0031
Week 8, postdose109.944 ± 38.2894345.526 ± 130.7682
Week 12, predose0.020 ± 0.10180.003 ± 0.0119
Week 12, postdose107.112 ± 35.8943331.531 ± 187.7316
Week 16, predose0.000 ± 0.00000.004 ± 0.0069
Week 240.001 ± 0.00260.003 ± 0.0070
Week 300.002 ± 0.00660.000 ± 0.0000
SecondaryChange From Baseline in C-reactive Protein (CRP)

Change from baseline in CRP were reported.

Time frame:
Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
Reported as:
Mean · Milligrams per liter
Change From Baseline in C-reactive Protein (CRP)
Milligrams per literGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Week 21.513 ± 7.61580.520 ± 6.85200.939 ± 5.5131
Week 4-0.243 ± 2.14020.238 ± 7.11980.302 ± 1.9397
Week 6-0.279 ± 2.2463-0.285 ± 6.7629-0.090 ± 2.1916
Week 80.026 ± 3.34600.361 ± 2.3499-0.121 ± 1.3529
Week 101.751 ± 1.86432.242 ± 5.10901.304 ± 1.3120
Week 120.918 ± 4.97960.765 ± 3.29340.139 ± 2.0962
Week 16-0.154 ± 2.1477-0.927 ± 7.66040.107 ± 1.5903
Week 200.735 ± 6.33741.020 ± 5.40010.267 ± 2.9934
Week 241.524 ± 9.45891.515 ± 6.65110.200 ± 1.9106
Week 300.789 ± 3.8812-0.716 ± 6.1862-0.176 ± 1.4461
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate (ESR)

Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.

Time frame:
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Reported as:
Mean · Millimeters per hour
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Millimeters per hourGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Week 2-0.037 ± 14.87680.100 ± 11.4682-6.816 ± 14.6283
Week 4-1.340 ± 13.7448-1.640 ± 12.3813-9.327 ± 16.4929
Week 810.602 ± 54.9277-0.005 ± 114.9206-28.010 ± 35.4705
Week 12-1.163 ± 17.9691-7.932 ± 17.5544-11.217 ± 14.6271
Week 16-5.213 ± 16.6053-7.225 ± 14.7691-12.500 ± 15.5616
Week 20-9.523 ± 21.9741-5.273 ± 16.7726-12.390 ± 15.4659
Week 24-6.118 ± 19.5332-5.261 ± 18.1322-9.653 ± 16.5951
Week 30-7.478 ± 20.4958-2.909 ± 17.3498-6.978 ± 19.1115
SecondaryChange From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4

Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.

Time frame:
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Reported as:
Mean · Grams per liter
Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4
Grams per literGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
IgG: Week 2-0.293 ± 2.5034-3.570 ± 1.5226-7.712 ± 3.2346
IgG: Week 4-0.274 ± 2.6898-4.612 ± 1.7211-8.904 ± 3.3077
IgG: Week 8-0.126 ± 2.6075-5.114 ± 1.7088-9.578 ± 4.1409
IgG: Week 12-0.051 ± 2.6476-5.231 ± 1.8415-9.899 ± 4.3507
IgG: Week 16-0.211 ± 2.9717-5.224 ± 2.0568-9.340 ± 4.3346
IgG: Week 20-0.217 ± 2.6829-4.942 ± 2.2000-9.976 ± 5.2069
gG: Week 24-0.171 ± 3.5555-4.360 ± 2.8371-9.467 ± 5.4390
IgG: Week 30-0.421 ± 4.0162-0.015 ± 2.3388-0.688 ± 4.9730
IgG1: Week 2-0.422 ± 2.4279-2.590 ± 1.1672-5.720 ± 2.6621
IgG1: Week 4-0.256 ± 2.8110-3.364 ± 1.8922-6.300 ± 2.7080
IgG1: Week 8-0.316 ± 2.4727-3.444 ± 2.2316-6.728 ± 3.0146
IgG1: Week 12-0.388 ± 2.6534-3.587 ± 2.7108-6.997 ± 2.8712
IgG1: Week 16-0.155 ± 2.7970-3.391 ± 2.7162-6.678 ± 3.3193
IgG1: Week 20-0.027 ± 2.9349-3.547 ± 4.3021-7.106 ± 3.1650
IgG1: Week 24-0.273 ± 3.4443-2.807 ± 3.8918-6.854 ± 3.3401
IgG1: Week 30-0.567 ± 3.8984-0.203 ± 3.9916-0.642 ± 4.0439
IgG2: Week 20.011 ± 0.5523-0.478 ± 0.5438-1.208 ± 0.8527
IgG2: Week 40.058 ± 0.5328-0.657 ± 0.6511-1.471 ± 1.0384
IgG2: Week 8-0.025 ± 0.5082-0.897 ± 0.6258-1.735 ± 1.0015
IgG2: Week 120.071 ± 0.4862-0.893 ± 0.6425-1.698 ± 1.0102
IgG2: Week 160.060 ± 0.5388-0.878 ± 0.7311-1.655 ± 1.0935
IgG2: Week 200.043 ± 0.5881-0.843 ± 0.7219-1.725 ± 1.0670
IgG2: Week 240.013 ± 0.6359-0.786 ± 0.8167-1.720 ± 1.0577
IgG2: Week 300.151 ± 0.6005-0.242 ± 0.6325-0.600 ± 0.7790
IgG3: Week 2-0.021 ± 0.1003-0.133 ± 0.1004-0.224 ± 0.1398
IgG3: Week 4-0.010 ± 0.1030-0.148 ± 0.1113-0.217 ± 0.1539
IgG3: Week 8-0.013 ± 0.0987-0.152 ± 0.1266-0.217 ± 0.1438
IgG3: Week 12-0.002 ± 0.1175-0.146 ± 0.1316-0.231 ± 0.1396
IgG3: Week 16-0.001 ± 0.1234-0.145 ± 0.1111-0.219 ± 0.1584
IgG3: Week 200.003 ± 0.1355-0.127 ± 0.1705-0.236 ± 0.1477
IgG3: Week 24-0.006 ± 0.1459-0.105 ± 0.1671-0.246 ± 0.1656
IgG3: Week 30-0.004 ± 0.1334-0.012 ± 0.0964-0.015 ± 0.0979
IgG4: Week 2-0.028 ± 0.1631-0.158 ± 0.4306-0.242 ± 0.2717
IgG4: Week 4-0.001 ± 0.0606-0.175 ± 0.4426-0.292 ± 0.3429
IgG4: Week 8-0.018 ± 0.1231-0.207 ± 0.4708-0.302 ± 0.3568
IgG4: Week 12-0.003 ± 0.1137-0.226 ± 0.5036-0.317 ± 0.3557
IgG4: Week 16-0.010 ± 0.1075-0.229 ± 0.5302-0.279 ± 0.2811
IgG4: Week 20-0.010 ± 0.0923-0.227 ± 0.5416-0.307 ± 0.3435
IgG4: Week 24-0.004 ± 0.0803-0.207 ± 0.5828-0.308 ± 0.3133
IgG4: Week 30-0.008 ± 0.1341-0.111 ± 0.5936-0.025 ± 0.1846
SecondaryChange From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21

Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.

Time frame:
Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
Reported as:
Median · chemiluminescent units (CU)
Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21
chemiluminescent units (CU)Group 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Anti-Ro60/SSA: Week 2-3.80 (-2480.00 to 893.30)-3327.70 (-10728.60 to -1492.30)-6838.30 (-20472.00 to -469.00)
Anti-Ro60/SSA: Week 490.80 (-87.90 to 3520.00)-5628.70 (-12174.20 to -2884.60)-8682.45 (-22604.00 to -882.15)
Anti-Ro60/SSA: Week 815.10 (-1480.00 to 1392.00)-6952.90 (-11828.00 to -2864.25)-11398.15 (-22522.35 to -925.20)
Anti-Ro60/SSA: Week 1641.25 (-2340.20 to 3792.00)-5424.00 (-8576.00 to -3201.10)-8511.15 (-20066.55 to -1637.40)
Anti-Ro60/SSA: Week 2456.70 (-1787.10 to 2398.90)-5702.50 (-13240.00 to -804.00)-8384.40 (-18053.85 to -619.55)
Anti-Ro60/SSA: Week 30-13.80 (-3208.15 to 2681.85)-73.60 (-2270.60 to 773.25)-39.90 (-2006.70 to 5976.00)
Anti-Ro52/TRIM21: Week 2-0.50 (-181.60 to 26.00)-490.80 (-1877.50 to -107.40)-496.30 (-1988.40 to 0.00)
Anti-Ro52/TRIM21: Week 4-0.45 (-170.20 to 24.40)-762.50 (-2876.90 to -277.25)-523.90 (-2412.50 to -24.70)
Anti-Ro52/TRIM21: Week 8-1.30 (-880.30 to 7.00)-732.60 (-1943.40 to -272.80)-611.40 (-3042.30 to 0.00)
Anti-Ro52/TRIM21: Week 16-0.05 (-430.60 to 253.80)-581.90 (-1741.30 to -249.10)-592.10 (-2494.10 to -21.90)
Anti-Ro52/TRIM21: Week 240.60 (-36.90 to 1098.10)-525.95 (-1488.90 to -29.20)-493.20 (-1397.60 to 0.00)
Anti-Ro52/TRIM21: Week 300.00 (-1031.80 to 184.40)0.90 (-233.80 to 768.00)0.00 (-167.75 to 507.75)
Anti-La/SSB: Week 20.00 (-3.70 to 6.00)-19.40 (-134.90 to -3.20)-25.30 (-346.10 to -2.60)
Anti-La/SSB: Week 40.00 (-3.80 to 10.20)-33.80 (-179.70 to -6.70)-38.90 (-369.90 to -6.00)
Anti-La/SSB: Week 8-0.15 (-18.45 to 7.00)-27.25 (-122.40 to -5.40)-44.60 (-507.90 to -5.20)
Anti-La/SSB: Week 160.00 (-3.60 to 56.50)-28.10 (-323.30 to -1.30)-46.50 (-530.50 to -9.20)
Anti-La/SSB: Week 241.10 (-5.35 to 53.10)-22.30 (-318.20 to 0.00)-40.80 (-2861.40 to -6.20)
Anti-La/SSB: Week 300.00 (-19.30 to 29.00)-1.40 (-29.60 to 6.80)-3.65 (-43.25 to 0.00)
SecondaryChange From Baseline in Autoantibodies: Rheumatoid Factor (RF)

Change from baseline in autoantibodies included RF were reported.

Time frame:
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Reported as:
Median · international unit per millilitre
Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)
international unit per millilitreGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Week 2-0.500 (-2.200 to 0.000)-1.700 (-4.500 to 0.000)-3.600 (-9.500 to 0.000)
Week 4-0.150 (-2.500 to 0.400)-3.300 (-6.600 to -0.600)-5.400 (-14.500 to -0.500)
Week 8-0.100 (-1.600 to 1.000)-3.200 (-6.000 to 0.000)-4.400 (-14.100 to 0.000)
Week 120.000 (-1.500 to 3.400)-2.700 (-4.700 to 0.000)-5.650 (-16.800 to -0.500)
Week 160.000 (-2.250 to 2.350)-3.450 (-6.900 to 0.000)-6.000 (-18.600 to -0.500)
Week 200.000 (-3.000 to 2.500)-2.900 (-5.900 to 0.000)-6.900 (-18.600 to 0.000)
Week 240.000 (-1.700 to 1.400)-2.850 (-5.950 to 0.000)-4.400 (-16.000 to 0.000)
Week 300.000 (-3.300 to 1.700)0.000 (-1.800 to 3.450)0.000 (-1.800 to 1.600)
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab

Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.

Time frame:
Baseline (Week 0) up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab
ParticipantsGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab4641
SecondaryNumber of Participants With Neutralising Antibodies (NAbs) to Nipocalimab

Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.

Time frame:
Baseline (Week 0) up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab
ParticipantsGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2w
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab3328

Adverse events

Collected over All-cause mortality: From screening (Week -6) up to Week 30; Serious and Other AEs: Post first administration of study intervention (Week 0) up to Week 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Placebo IV q2w0/56 (0%)3/56 (5.4%)22/56 (39.3%)
Group 2: Nipocalimab 5 mg/kg q2w0/53 (0%)4/53 (7.5%)35/53 (66%)
Group 3: Nipocalimab 15 mg/kg q2w0/54 (0%)4/54 (7.4%)32/54 (59.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg q2wGroup 3: Nipocalimab 15 mg/kg q2w
Anaphylactic ReactionImmune system disorders0/561/530/54
AppendicitisInfections and infestations0/561/530/54
Covid-19Infections and infestations0/561/530/54
ErythemaSkin and subcutaneous tissue disorders0/561/530/54
Genital Herpes SimplexInfections and infestations0/560/531/54
Anembryonic GestationPregnancy, puerperium and perinatal conditions0/560/531/54
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/560/531/54
Pulmonary MassRespiratory, thoracic and mediastinal disorders0/560/531/54
Cardiac Failure CongestiveCardiac disorders1/560/530/54
Acute SinusitisInfections and infestations1/560/530/54
Most frequent other events
Showing 10 of 18
Most frequent other events
EventGroup 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg q2wGroup 3: Nipocalimab 15 mg/kg q2w
DiarrheaGastrointestinal disorders2/563/538/54
HeadacheNervous system disorders8/564/536/54
Covid-19Infections and infestations3/567/533/54
NasopharyngitisInfections and infestations4/564/537/54
Upper Respiratory Tract InfectionInfections and infestations4/566/533/54
NauseaGastrointestinal disorders2/560/536/54
FatigueGeneral disorders6/563/536/54
Abdominal Pain UpperGastrointestinal disorders2/564/531/54
ConjunctivitisInfections and infestations3/564/531/54
Urinary Tract InfectionInfections and infestations3/564/533/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2wTotal
<=18 years0000
Between 18 and 65 years504948147
>=65 years64616
Age, Continuous
Age, Continuous(years)Group 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2wTotal
Mean47.3 ± 12.648.3 ± 11.8348.6 ± 12.0748.1 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2wTotal
Female524950151
Male44412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2wTotal
Hispanic or Latino1023
Not Hispanic or Latino555352160
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2wTotal
American Indian or Alaska Native0000
Asian53412
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White504949148
More than one race0000
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(Participants)Group 1: Placebo IV q2wGroup 2: Nipocalimab 5 mg/kg IV q2wGroup 3: Nipocalimab 15 mg/kg IV q2wTotal
France1023
Germany1012830
Italy0101
Japan2327
Poland30303090
Portugal0011
Spain1012
Taiwan3014
United States97925
08

Study locations

69 sites
  • Anniston Medical Clinic
    Anniston, Alabama 36207, United States
  • Arizona Arthritis and Rheumatology Research PLLC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • St. Jude Heritage Medical Group
    Fullerton, California 92835, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • Colorado Arthritis Associates
    Denver, Colorado 80228, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Rheumatology Associates Of South Florida
    Boca Raton, Florida 33486, United States
  • Bay Area Arthritis and Osteoporosis
    Brandon, Florida 33511, United States
  • Centre for Rheumatology, Immunology and Arthritis
    Fort Lauderdale, Florida 33309, United States
  • University of Florida Health Jacksonville
    Jacksonville, Florida 32209, United States
  • Omega Research Consultants
    Orlando, Florida 32835, United States
  • Clinical Investigation Specialists
    Gurnee, Illinois 60031, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • St. Paul Rheumatology P A
    Eagan, Minnesota 55121, United States
  • North Mississippi Medical Clinics
    Tupelo, Mississippi 38801, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Columbia Arthritis Center
    Columbia, South Carolina 29204, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Dr. Ramesh Gupta
    Memphis, Tennessee 38119, United States
  • Austin Regional Clinic
    Austin, Texas 78731-3146, United States
  • Trinity Clinical Research, LLC
    Carrollton, Texas 75007, United States
  • CHU de Grenoble Hopital Albert Michallon
    La Tronche, 38700, France
  • Centre Hospitalier Le Mans
    Le Mans, 72037, France
  • Hopital Saint Joseph
    Marseille, 13285, France
  • Hopital Pitie Salpetriere
    Paris, 75013, France
  • CHRU Hôpital de Hautepierre
    Strasbourg, 67098, France
  • Charite Universitaetsmedizin Berlin
    Berlin, 10117, Germany
  • Uniklinik Köln
    Cologne, 50923, Germany
  • Universitatsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Hamburger Rheuma Forschungszentrum II
    Hamburg, 20095, Germany
  • medius KLINIK KIRCHHEIM
    Kirchheim unter Teck, 73230, Germany
  • Universitatsklinikum Tubingen
    Tübingen, 72076, Germany
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
    Brescia, 25123, Italy
  • P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
    Catania, 95100, Italy
  • IRCCS Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
    Palermo, 90129, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, 37126, Italy
  • Tokyo Metropolitan Tama Medical Center
    Fuchū, 183 8524, Japan
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
  • Hokkaido University Hospital
    Sapporo, 060-8648, Japan
  • St. Luke's International Hospital
    Tokyo, 104 8560, Japan
  • Nihon University Itabashi Hospital
    Tokyo, 173 8610, Japan
  • University of Tsukuba Hospital
    Tsukuba, 305-8520, Japan
  • Medisch Centrum Leeuwarden
    Leeuwarden, 8934 AD, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • Nasz Lekarz Przychodnie Medyczne
    Bydgoszcz, 85-065, Poland
  • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Zespolu Opieki Zdrowotnej w Konskich
    Gmina Końskie, 26 200, Poland
  • Malopolskie Badania Kliniczne Sp z o o
    Krakow, 30-002, Poland
  • REUMED Zespol Poradni Specjalistycznych Filia nr 2
    Lublin, 20-607, Poland
  • Centrum Medyczne
    Poznan, 61 113, Poland
  • Medycyna Kliniczna
    Warsaw, 00-874, Poland
  • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
    Warsaw, 02 637, Poland
  • Centrum Medyczne AMED Targowek
    Warsaw, 03 291, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52 415, Poland
  • Instituto Portugues de Reumatologia
    Lisbon, 1050-034, Portugal
  • ULSAM, EPE - Hospital Conde de Bertiandos
    Ponte de Lima, 4990-078, Portugal
  • Hosp Univ A Coruna
    A Coruña, 15006, Spain
  • Hosp Reina Sofia
    Córdoba, 14004, Spain
  • Hosp. de Merida
    Mérida, 6800, Spain
  • Corporacio Sanitari Parc Tauli
    Sabadell, 08208, Spain
  • Hosp Clinico Univ de Salamanca
    Salamanca, 37007, Spain
  • Hosp. Infanta Luisa
    Seville, 41010, Spain
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
  • Chang Gung Memorial Hospital Linkou Branch
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Yu F, Myshkin E, Nguyen B, Bobadilla Mendez C, Cossu M, Fei K, Wang Q, Hubbard JJ, Campbell K, Ramchandren S, Rojo Cella R, Edwards R, Taylor PC, Gottenberg JE, Noaiseh G, Vu T, Antozzi C, Winthrop KL, Cuff CA, Loza MJ, Dimitrova D, Gao S. Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. Hum Vaccin Immunother. 2026 Dec;22(1):2664331. doi: 10.1080/21645515.2026.2664331. Epub 2026 May 5. PubMed 42084498 ↗
  • Noaiseh G, Sivils KL, Campbell K, Idokogi J, Lo KH, Liva SG, Leu JH, Dhatt H, Ma K, Leonardo S, Li H, Hubbard JJ, Gottenberg JE. Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjogren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial. Lancet. 2025 Nov 22;406(10518):2435-2448. doi: 10.1016/S0140-6736(25)01430-8. Epub 2025 Oct 24. PubMed 41284548 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2023, 25 months.

Results were first posted in Nov 2026, 3 years after primary completion. A results delay was requested in Oct 2024.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2021
First posted
Jul 20, 2021
StartActual
Sep 21, 2021
Primary completionActual
Oct 23, 2023
CompletionActual
Nov 30, 2023
Results delay requested
Oct 18, 2024
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline in Clinical European League Against Rheumatism Sjogren(EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
Nov 5, 2026
Documents
Secondary outcomes
15 edited, 6 added, 2 removed
What changed in the outcomes
  • EditedChange fromFrom Baseline in European League Against Rheumatism (EULAR) SjogrenEULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
  • EditedPercentage of Participants With Improvement of Greater thanThan or Equal to (>=) 4 Points fromFrom Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score (Minimal Clinically Important Improvement) at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
  • EditedPercentage of Participants With Improvement of >= 4 Points fromFrom Baseline in clinESSDAI Score (Minimal Clinically Important Improvement) at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
  • EditedPercentage of Participants With Disease Response as Assessed byAccording to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24Time frame: Week 24 → At Week 24
  • EditedPercentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24Time frame: Week 24 → At Week 24
  • EditedPercentage of Participants With Improvement fromFrom Baseline in >= 3 of 5 Composite of Relevant Endpoints for SjogrenSjögren's Syndrome (CRESS) Categories at Week 24Time frame: Baseline to Week 24 → At Week 24
  • EditedPercentageNumber of Participants withWith Treatment-emergent Adverse Events (TEAEs) Through End of Study VisitTime frame: Up to 30 weeks → Post first administration of study intervention (Week 0) up to Week 30
  • EditedPercentageNumber of Participants withWith Treatment-emergent Adverse Events of Special interestsInterests (AESIs) Through End of Study VisitTime frame: Up to 36 weeks → Post first administration of study intervention (Week 0) up to Week 30
  • EditedPercentageNumber of Participants withWith Treatment-emergent Serious Adverse Events (SAEs) Through End of Study VisitTime frame: Up to 30 weeks → Post first administration of study intervention (Week 0) up to Week 30
  • EditedPercentageNumber of Participants withWith TEAEs Leading to Treatment Discontinuation Through End of Study VisitTime frame: Up to 30 weeks → Post first administration of study intervention (Week 0) up to Week 30
  • EditedPercentageNumber of Participants withWith Clinically Significant Abnormalities in Vital SignsTime frame: Up to 36 weeks → Post first administration of study intervention (Week 0) up to Week 30
  • EditedPercentageNumber of Participants withWith Clinically Significant Abnormalities in Laboratory ParametersTime frame: Up to 36 weeks → Weeks 2, 4, 8, 12, 16, 20, 24, and 30
  • EditedSerum Nipocalimab Concentration of Nipocalimab Over TimeTime frame: Up to Week 30 → Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
  • EditedNumber of Participants with Antibodies to Nipocalimab (With Anti-drug Antibodies [(ADAs] and Neutralizing Antibodies [NAbs])) to NipocalimabTime frame: Up to Week 36 → Baseline (Week 0) up to Week 30
  • EditedNumber of Participants with Change fromFrom Baseline in Autoantibodies: Rheumatoid Factor (RF)Time frame: Baseline to Week 36 → Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
  • AddedPercentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24Time frame: Baseline (Week 0), Week 24
  • AddedChange From Baseline in C-reactive Protein (CRP)Time frame: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
  • AddedChange From Baseline in Erythrocyte Sedimentation Rate (ESR)Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
  • AddedChange From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
  • AddedChange From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21Time frame: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
  • AddedNumber of Participants With Neutralising Antibodies (NAbs) to NipocalimabTime frame: Baseline (Week 0) up to Week 30
  • RemovedESSPRI Response at Week 24Time frame: Week 24
  • RemovedNumber of Participants with Change from Baseline in BiomarkersTime frame: Baseline to Week 36
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline in Clinical European League Against Rheumatism Sjogren(EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
    Secondary outcomes 15 edited, 6 added, 2 removed
    What changed in the outcomes
    • EditedChange fromFrom Baseline in European League Against Rheumatism (EULAR) SjogrenEULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
    • EditedPercentage of Participants With Improvement of Greater thanThan or Equal to (>=) 4 Points fromFrom Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score (Minimal Clinically Important Improvement) at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
    • EditedPercentage of Participants With Improvement of >= 4 Points fromFrom Baseline in clinESSDAI Score (Minimal Clinically Important Improvement) at Week 24Time frame: Baseline to Week 24 → Baseline (Week 0), Week 24
    • EditedPercentage of Participants With Disease Response as Assessed byAccording to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24Time frame: Week 24 → At Week 24
    • EditedPercentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24Time frame: Week 24 → At Week 24
    • EditedPercentage of Participants With Improvement fromFrom Baseline in >= 3 of 5 Composite of Relevant Endpoints for SjogrenSjögren's Syndrome (CRESS) Categories at Week 24Time frame: Baseline to Week 24 → At Week 24
    • EditedPercentageNumber of Participants withWith Treatment-emergent Adverse Events (TEAEs) Through End of Study VisitTime frame: Up to 30 weeks → Post first administration of study intervention (Week 0) up to Week 30
    • EditedPercentageNumber of Participants withWith Treatment-emergent Adverse Events of Special interestsInterests (AESIs) Through End of Study VisitTime frame: Up to 36 weeks → Post first administration of study intervention (Week 0) up to Week 30
    • EditedPercentageNumber of Participants withWith Treatment-emergent Serious Adverse Events (SAEs) Through End of Study VisitTime frame: Up to 30 weeks → Post first administration of study intervention (Week 0) up to Week 30
    • EditedPercentageNumber of Participants withWith TEAEs Leading to Treatment Discontinuation Through End of Study VisitTime frame: Up to 30 weeks → Post first administration of study intervention (Week 0) up to Week 30
    • EditedPercentageNumber of Participants withWith Clinically Significant Abnormalities in Vital SignsTime frame: Up to 36 weeks → Post first administration of study intervention (Week 0) up to Week 30
    • EditedPercentageNumber of Participants withWith Clinically Significant Abnormalities in Laboratory ParametersTime frame: Up to 36 weeks → Weeks 2, 4, 8, 12, 16, 20, 24, and 30
    • EditedSerum Nipocalimab Concentration of Nipocalimab Over TimeTime frame: Up to Week 30 → Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
    • EditedNumber of Participants with Antibodies to Nipocalimab (With Anti-drug Antibodies [(ADAs] and Neutralizing Antibodies [NAbs])) to NipocalimabTime frame: Up to Week 36 → Baseline (Week 0) up to Week 30
    • EditedNumber of Participants with Change fromFrom Baseline in Autoantibodies: Rheumatoid Factor (RF)Time frame: Baseline to Week 36 → Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
    • AddedPercentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24Time frame: Baseline (Week 0), Week 24
    • AddedChange From Baseline in C-reactive Protein (CRP)Time frame: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
    • AddedChange From Baseline in Erythrocyte Sedimentation Rate (ESR)Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
    • AddedChange From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
    • AddedChange From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21Time frame: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
    • AddedNumber of Participants With Neutralising Antibodies (NAbs) to NipocalimabTime frame: Baseline (Week 0) up to Week 30
    • RemovedESSPRI Response at Week 24Time frame: Week 24
    • RemovedNumber of Participants with Change from Baseline in BiomarkersTime frame: Baseline to Week 36
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04968912
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Sep 21, 2021
Primary completion
Oct 23, 2023
Completion
Nov 30, 2023
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion